department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Winlevi · pharmadog

pharmadog
drugs
Winlevi

drug

patient view →

clascoterone

Marketedupdated 2mo ago

by Sun Pharmaceutical Industries Ltd

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for acne and 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Winlevi

generic

clascoterone

MOA

Androgen Receptor antagonist

indication

Acne Vulgaris

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 12, 2027

189 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jul 25, 2030formulationUS 87854274.1y
Feb 28, 2029formulationUS 94336282.6y
Nov 20, 2028formulationUS 112073322.4y
Aug 14, 2028method-of-use (U-2942)US 101596822.1y
Jul 24, 2028formulationUS 119381412.0y
Jul 24, 2028formulationUS 123370022.0y
Jul 24, 2028method-of-use (U-2942)US 94864582.0y
Jan 12, 2027method-of-use (U-2942)US 8143240189d

Data sources

ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 7

drugCB-03111 co-mentions · 1 sources
druglatanoprost SR1 co-mentions · 1 sources
drugLATANOPROST1 co-mentions · 1 sources
drugXalatan1 co-mentions · 1 sources
drug(clascoterone + latanoprost)1 co-mentions · 1 sources
companyGlenmark Pharmaceuticals Ltd1 co-mentions · 1 sources
tagDermatology1 co-mentions · 1 sources

Trials studying clascoterone

phase3A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Lossactive not recruitingn=703
phase31% Clascoterone Cream for the Treatment Acne Vulgarisnot yet recruitingn=692
phase4A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patientsactive not recruitingn=10
phase4A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acnecompletedn=10
phase3A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)completedn=762
phase4A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acnecompletedn=20
phase4A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acnecompletedn=10
phase3Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgarisrecruitingn=692

more trials →